Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02457065
Other study ID # 00028495 D15090
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2015
Est. completion date January 2016

Study information

Verified date December 2018
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A patient's sun-related behavior greatly influences the likelihood of that patient developing melanoma, the most dangerous form of skin cancer. Prior research shows current educational strategies on inducing preventative behaviors such as wearing sun-protection clothing and wearing sunscreen are inadequate at effectively changing behavior when used in isolation -- patients are aware of the dangers of not engaging in these preventative measures but forgo them nonetheless.

The investigators are researching methods to positively influence skin cancer prevention behaviors among melanoma survivors and their families. The first objective of this study is to compare patient and familial sun exposure and cancer screening activity before and after a patient's diagnosis with primary melanoma. The second objective of this study is to note if hanging a "Melanoma Survivor" plaque in a melanoma survivor's bathroom will significantly affect the survivor's and broader family's sun exposure and cancer screening activity.

The investigators' sample of patients consists of survivors of primary cutaneous melanoma less than 4.0 mm in depth who came through the Dermatology Clinic at Dartmouth-Hitchcock Medical Center and voluntarily chose to participate in the study after being informed of the nature of the research. These patients completed a confidential survey assessing sun exposure related activities immediately before and after their diagnosis. After the participants filled out the survey, the investigators asked the participants if they could nominate a family member to whom the investigators could explain the purpose of this research study to and confidentially ask an additional set of questions to evaluate the broader impact of a melanoma diagnosis. From the investigators' original sample, the investigators randomly chose a few families who would display the survivor plaque in their primary bathroom. After six-to-twelve months, during the each patient's follow up visit, the investigators asked the patient and the patient's nominated family member to fill out another survey to assess sun exposure related activity.

On the surveys, no names were recorded. Everything was anonymous.


Description:

This study is investigating a method to positively influence skin cancer prevention behaviors among melanoma survivors and their families. The first objective is to compare patient and familial sun exposure and cancer screening activity before and after a patient's diagnosis with primary cutaneous melanoma less than 4.0 mm in depth. It is believed that the diagnosis will positively affect behavior regarding skin cancer prevention as the diagnosis of melanoma makes the risk associated with sun-exposure and skin cancer a tangible issue. The second objective is to test whether receiving a "Melanoma Survivor" plaque and posting it in a melanoma survivor's bathroom will significantly affect the survivor's and broader family's sun exposure and cancer screening activity. Marketing research has shown similar techniques have been effective in causing individuals to consume goods (e.g. getting free pens with company logos makes you more likely to buy goods from that company), and the investigators think such techniques are transferable into the field of public health.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- patient has melanoma diagnosis within past 10 years less than 4mm in depth

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
"Melanoma Survivor" plaque
The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.

Locations

Country Name City State
United States Dartmouth-Hitchcock Medical Center (Heater Road) Lebanon New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. Subjects filled out a survey when they enrolled in the study assessing their skin cancer prevention behaviors. Survey questions asked the patient and a family member of theirs to comment on patient and familial sun exposure and cancer screening activity before and after the patient's diagnosis with primary melanoma. Subjects self-reported if the diagnosis changed their behavior. Collected via a survey administered immediately after a subject enrolled in the study.
Primary Influence of a "Melanoma Survivor" Plaque on the Survivor's and Broader Family's Skin Cancer Prevention Activity. Subjects filled out a survey when they enrolled in the study assessing their skin cancer prevention behaviors. The investigators randomly gave some subjects a "Melanoma Survivor" plaque. After 6-12 months, the subjects again filled out a survey assessing their skin cancer prevention behaviors. The investigators analyzed the difference in each subject's responses to the same survey questions over time. The investigators then analyzed the difference between the responses of the subjects who saw the plaque and the subjects who did not see the plaque to discern the influence of the plaque on skin cancer prevention behaviors. Survey questions asked the patient and a family member of theirs to comment on patient and familial sun exposure and cancer screening activity. Subjects self-reported if the their behavior changed over time. 6-12 months between time of completion of first survey and second survey.
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study